Last reviewed · How we verify
NCT06612515: RESPONSE
Vaccine-induced Immunity in Immunocompromised Patients
trial in Immunodeficiency in 5,000 participants. Currently enrolling.
30 April 2029
Quick facts
| Lead sponsor | University of Cologne |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 5,000 |
| Start date | 25 March 2025 |
| Primary completion | 30 April 2029 |
| Estimated completion | 31 December 2029 |
| Sites | 1 location across Germany |
Conditions studied
- Immunodeficiency — all drugs for Immunodeficiency →
Sponsor
University of Cologne
Who can join
18 and older, any sex, with Immunodeficiency. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Managing respiratory virus infections in immunocompromised patients requires a multidisciplinary approach, including vaccination, though its effectiveness is often suboptimal in these individuals. In hematological patients, poor humoral immunogenicity is common, especially when the B cell axis is affected by disease or treatment, while T cell responses may offer better protection. Current immunologic data on these patients is limited, focusing mostly on serologic parameters. To address this, we will conduct an observational study analyzing early and late booster vaccinations, with a focus on virus-specific T cell responses in vaccinated patients.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06612515
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Immunodeficiency
Currently open trials in the same condition.
- NCT06248957 — SYSTEMS-LEVEL ANALYSES OF IMMUNE DYSREGULATION · recruiting
- NCT05907746 — Allogeneic Hematopoietic Stem Cell Transplantation With Briquilimab-Based Conditioning in Participants With GATA2 Defici · Phase 2 · active not recruiting
- NCT05587894 — OPtimisation of Antiviral Therapy in Immunocompromised COVID-19 Patients: a Randomized Factorial Controlled Strategy Tri · Phase 2 · recruiting
- NCT07406217 — OPtimisation of Antiviral Therapy in Immunocompromised COVID-19 Patients · Phase 2 · recruiting
- NCT05027945 — A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplant for Subjects With VEXAS (Vacuoles, E1 Enzyme, X-linked · Phase 2 · recruiting
Other University of Cologne trials
Trials by the same sponsor.
- NCT07280585 — STOP-PKD: SGLT2-inhibition to Improve Prognosis in Polycystic Kidney Disease · Phase 3 · recruiting
- NCT06781710 — Analysis of the Epidemiology, Clinical Presentation and Therapy as Well as Therapy-associated Risk of Demyelination Synd · recruiting
- NCT05969431 — Hair Cortisol as Marker of Chronic Stress in Preterm and Term Fathers - Fathair-study · recruiting
- NCT05876221 — Platelet Response to Caplacizumab in the Treatment of Acquired Thrombotic Thrombocytopenic Purpura · completed
- NCT06496711 — IMPLEMENT - Model Project for Quality-assured Exercise Therapy for Cancer Patients · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06612515 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Cologne
- Last refreshed: 30 March 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06612515.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing